PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Federal Momentum Advancing Psychedelic Therapeutics Development 

Silo Pharma (NASDAQ: SILO) commented on a series of coordinated U.S. federal actions accelerating the development of psychedelic-based therapies for mental health and substance use disorders, citing new funding initiatives, clinical progress and regulatory advancements. The company pointed to programs from agencies including ARPA-H and the FDA, such as IND clearance for a noribogaine candidate and the issuance of priority […]